+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-09-08Number of Pages: 154

Radiodermatitis Market (Product type - Topical (Corticosteroids, Hydrophilic Creams, and Topical Antibiotics), Oral Medication (Corticosteroids, Oral Analgesics, Antibiotics), and Dressings (Hydrogel, Hydrocolloid, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressing (GM-CSF Gauze and Silver Leaf Dressing); By Distribution Channel - Hospital Pharmacy, Retail Pharmacy Store, and Online Store) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Radiodermatitis Market: Snapshot

The global radiodermatitis market has been witnessing a significant progress over the last few years on the grounds of the rising prevalence of cancer and the growing uptake of radiation therapy for its treatment. Thanks to the increasing focus on product innovations and advancements in existing products, the market is also showing high potential for future growth.

Over the coming years, the unmet medical needs of consumers in emerging regions is expected to open a plethora of growth opportunities for market players, leading to a substantial rise in this market. Expanding at a CAGR of 3.90% over the period from 2016 to 2024, the market, which stood at US$299.6 mn in 2015, is anticipated to increase to US$421.5 mn by the end of the forecast period.

radiodermatitis-market

 

Asia Pacific to Retain Leadership in Global Radiodermatitis Market

Spread across Asia Pacific, the Middle East and Africa, North America, Latin America, and Europe, the market for radiodermatitis boasts of a robust presence across the world. Asia Pacific, among all, has been leading the global radiodermatitis market, thanks to a higher percentage of patients eligible for radiotherapy. The increasing pool of cancer patients is expected to drive the Asia Pacific radiodermatitis market further, ensuring its dominance over the next few years. Since a number of Asian economies, situated in the tropical region, have humid weather conditions, the severity of radiation dermatitis is significantly high in this geographical segment, which is also expected to boost the market for radiodermatitis in Asia Pacific in the near future.

Amongst other regional markets for radiodermatitis, Europe also possesses a considerable share in the global market on account of the increase in research and development activities in life sciences, upswing in academic research in radiation dermatitis, and the escalating number of product launches in this region. The market in North America has been driven by the presence of a large pool of well-established pharmaceutical enterprises, research organizations, and several government institutes, which actively work on developing a standard treatment solution for radiodermatitis.

Latin America and the Middle East and Africa are likely to gain considerably from the increasing attention of multinational companies on them. The large base of the unprivileged population, particularly in the Middle East and central Africa, and the implementation of new policies encouraging the uptake of radiotherapy in these regions are anticipated to boost the radiodermatitis markets in Latin America and the Middle East and Africa.

Topical Agents to Continue Being Most Valued Radiodermatitis Products

Topical, oral medication, and dressings are the main products available in the global market for radiodermatitis. Topical agents witness a higher demand from end users than other radiodermatitis products and are anticipated to continue doing so over the next few years. The ease of availability and cost benefits of topical products have fueled their demand among all strata of consumers, which is likely to reflect positively on their sales in the near future.

Corticosteroid creams, hydrophilic creams, and topical antibiotics are most preferred topical products across the world. Hydrophilic creams report a much higher demand than the other two. Analysts expect this scenario to remain so over the years to come.

Stratpharma AG, Smith & Nephew Plc, Molnlycke Health Care, Intermed Pharmaceuticals, Derma Sciences Inc., ConvaTec Inc., BMG Pharma S.r.l., Acelity LP Inc., and 3M are the key participants in the global Radiodermatitis market.

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Radiodermatitis Market

Chapter 4. Market Overview
4.1. Introduction
4.2. Market Dynamics
      4.2.1. Drivers
      4.2.2. Restraints
      4.2.3. Opportunity
4.3. Value Chain Analysis

Chapter 5. Global Radiodermatitis Market Analysis and Forecast, by Product
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Product
      5.3.1. Topical
               5.3.1.1. Corticosteroids
               5.3.1.2. Hydrophilic Creams
               5.3.1.3. Others (topical antibiotics)
      5.3.2. Oral Medication
               5.3.2.1. Corticosteroids
               5.3.2.2. Others (analgesics, antibiotics, etc.)
      5.3.3. Dressings
               5.3.3.1. Hydrogel
               5.3.3.2. Hydrocolloid
               5.3.3.3. No Sting Barrier Film
               5.3.3.4. Honey Impregnated Gauze
               5.3.3.5. Silicone Coated Dressing
               5.3.3.6. Others (silver leaf dressings, GM-CSF gauze, etc.)
5.4. Market Attractiveness Analysis, by Product, 2015
5.5. Key Trends

Chapter 6. Global Radiodermatitis Market Analysis and Forecast, by Distribution Channel
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Distribution Channel
      6.3.1. Hospital Pharmacy
      6.3.2. Retail Pharmacy Store 
      6.3.3. Online Store
6.4. Market Attractiveness Analysis, by Distribution Channel, 2015

Chapter 7. Pipeline Analysis
7.1. List of discontinued trials
7.2. Clinical trial data for open studies

Chapter 8. Global Radiodermatitis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Region
      8.3.1. North America
      8.3.2. Europe
      8.3.3. Asia Pacific
      8.3.4. Latin America
      8.3.5. Middle East & Africa
8.4. Market Attractiveness Analysis, by Region, 2015
8.5. Key Trends

Chapter 9. North America Radiodermatitis Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Product 
      9.3.1. Topical
      9.3.2. Oral Medication
      9.3.3. Dressings
9.4. Market Size (US$ Mn) Forecast, by Distribution Channel
      9.4.1. Hospital Pharmacy
      9.4.2. Retail Pharmacy Store
      9.4.3. Online Store
9.5. Market Size (US$ Mn) Forecast, by Country
      9.5.1. U.S.
      9.5.2. Canada
9.6. Market Attractiveness Analysis, by Product, 2015
9.7. Market Attractiveness Analysis, by Distribution Channel, 2015
9.8. Key Trends

Chapter 10. Europe Radiodermatitis Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Product 
      10.3.1. Topical
      10.3.2. Oral Medication
      10.3.3. Dressings
10.4. Market Size (US$ Mn) Forecast, by Distribution Channel
      10.4.1. Hospital Pharmacy
      10.4.2. Retail Pharmacy Store
      10.4.3. Online Store
10.5. Market Size (US$ Mn) Forecast, by Country
      10.5.1. U.K.
      10.5.2. Germany
      10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis, by Product, 2015 
10.7. Market Attractiveness Analysis, by Distribution Channel, 2015
10.8. Key Trends

Chapter 11. Asia Pacific Radiodermatitis Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product 
      11.3.1. Topical
      11.3.2. Oral Medication
      11.3.3. Dressings
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
      11.4.1. Hospital Pharmacy
      11.4.2. Retail Pharmacy Store
      11.4.3. Online Store
11.5. Market Size (US$ Mn) Forecast, by Country
      11.5.1. China
      11.5.2. Japan
      11.5.3. Rest of Asia Pacific
11.6. Market Attractiveness Analysis, by Product, 2015 
11.7. Market Attractiveness Analysis, by Distribution Channel, 2015
11.8. Key Trends

Chapter 12. Latin America Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Product 
      12.3.1. Topical
      12.3.2. Oral Medication
      12.3.3. Dressings
12.4. Market Size (US$ Mn) Forecast, by Distribution Channel
      12.4.1. Hospital Pharmacy
      12.4.2. Retail Pharmacy Store
      12.4.3. Online Store
12.5. Market Size (US$ Mn) Forecast, by Country
      12.5.1. Brazil
      12.5.2. Mexico
      12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis, by Product, 2015 
12.7. Market Attractiveness Analysis, by Distribution Channel, 2015
12.8. Key Trends

Chapter 13. Middle East & Africa Radiodermatitis Market Analysis and Forecast
13.1. Key Findings
13.2. Introduction
13.3. Market Size (US$ Mn) Forecast, by Product 
      13.3.1. Topical
      13.3.2. Oral Medication
      13.3.3. Dressings
13.4. Market Size (US$ Mn) Forecast, by Distribution Channel
      13.4.1. Hospital Pharmacy
      13.4.2. Retail Pharmacy Store
      13.4.3. Online Store
13.5. Market Size (US$ Mn) Forecast, by Country
      13.5.1. UAE
      13.5.2. South Africa
      13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis, by Product, 2015 
13.7. Market Attractiveness Analysis, by Distribution Channel, 2015
13.8. Key Trends

Chapter 14. Competition Landscape
14.1. Market Share Analysis
14.2. Competition Matrix
14.3. Company Profiles
      14.3.1. 3M 
               14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.1.2. Financial Overview
               14.3.1.3. Product Portfolio
               14.3.1.4. SWOT Analysis
               14.3.1.5. Strategic Overview
      14.3.2. Acelity LP, Inc.
               14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
               14.3.2.2. Financial Overview
               14.3.2.3. Product Portfolio
               14.3.2.4. SWOT Analysis
               14.3.2.5. Strategic Overview
      14.3.3. BMG Pharma S.r.l.
               14.3.3.1. Company Overview (HQ, business segments, employee strength)
               14.3.3.2. Product Portfolio
               14.3.3.3. SWOT Analysis
               14.3.3.4. Recent Developments
               14.3.3.5. Strategic Overview
      14.3.4. ConvaTec, Inc.
               14.3.4.1. Company Overview (HQ, business segments, employee strength)
               14.3.4.2. Financial Overview
               14.3.4.3. Product Portfolio
               14.3.4.4. SWOT Analysis
               14.3.4.5. Strategic Overview
      14.3.5. Derma Sciences Inc.
               14.3.5.1. Company Overview (HQ, business segments, employee strength)
               14.3.5.2. Financial Overview
               14.3.5.3. Product Portfolio
               14.3.5.4. SWOT Analysis
               14.3.5.5. Strategic Overview
      14.3.6. Intermed Pharmaceuticals
               14.3.6.1. Company Overview (HQ, business segments, employee strength)
               14.3.6.2. Product Portfolio
               14.3.6.3. SWOT Analysis
               14.3.6.4. Recent Developments
               14.3.6.5. Strategic Overview
      14.3.7. Molnlycke Health Care
               14.3.7.1. Company Overview (HQ, business segments, employee strength)
               14.3.7.2. Financial Overview
               14.3.7.3. Product Portfolio
               14.3.7.4. SWOT Analysis
               14.3.7.5. Strategic Overview
      14.3.8. Smith & Nephew plc
               14.3.8.1. Company Overview (HQ, business segments, employee strength)
               14.3.8.2. Financial Overview
               14.3.8.3. Product Portfolio
               14.3.8.4. SWOT Analysis
               14.3.8.5. Strategic Overview
      14.3.9. Stratpharma AG
               14.3.9.1. Company Overview (HQ, business segments, employee strength)
               14.3.9.2. Product Portfolio
               14.3.9.3. SWOT Analysis
               14.3.9.4. Strategic Overview
               14.3.9.5. Value Chain
      14.3.10. Others

List of Figures

Figure 1: Global Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 2: Global Radiodermatitis Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 3: Global Topical Products Market Revenue (US$ Mn), 2014–2024
Figure 4: Global Oral Medication Market Revenue (US$ Mn), 2014–2024
Figure 5: Global Dressings Market Revenue (US$ Mn), 2014–2024
Figure 6: Global Topical Corticosteroids Market Revenue (US$ Mn), 2014–2024
Figure 7: Global Hydrophilic Creams Market Revenue (US$ Mn), 2014–2024
Figure 8: Global Other Topical agents Market Revenue (US$ Mn), 2014–2024
Figure 9: Global Oral Analgesic, Anti-inflammatory & Antibiotic Market Revenue (US$ Mn), 2014-2024
Figure 10: Global Oral Corticosteroids Market Revenue (US$ Mn), 2014–2024
Figure 11: Global Hydrogel Market Revenue (US$ Mn), 2014–2024
Figure 12: Global Hydrocolloid Market Revenue (US$ Mn), 2014–2024
Figure 13: Global No Sting Barrier Film Market Revenue (US$ Mn), 2014–2024
Figure 14: Global Honey Impregnated Gauze Market Revenue (US$ Mn), 2014–2024
Figure 15: Global Silicone Coated Dressing Market Revenue (US$ Mn), 2014–2024
Figure 16: Global Other Dressings Market Revenue (US$ Mn), 2014–2024
Figure 17: Radiodermatitis Market Attractiveness Analysis, by Product Type
Figure 18: Global Radiodermatitis Market Value Share Analysis, by Distribution Channel, 2015 and 2024
Figure 19: Global Hospital Pharmacy Market Revenue (US$ Mn), 2014–2024
Figure 20: Global Retail Pharmacy Store Market Revenue (US$ Mn), 2014–2024
Figure 21: Global Online Store Market Revenue (US$ Mn), 2014–2024
Figure 22: Radiodermatitis Market Attractiveness Analysis, by Distribution Channel, 2015
Figure 23: Global Radiodermatitis Market Value Share Analysis, by Region, 2015 and 2024
Figure 24: Radiodermatitis Market Attractiveness Analysis, by Region, 2015
Figure 25: North America Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 26: North America Market Attractiveness Analysis, by Country, 2015
Figure 27: North America Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 28: North America Market Value Share Analysis, by Distribution Channel, 2015 and 2024
Figure 29: North America Market Value Share Analysis, by Country, 2015 and 2024
Figure 30: North America Market Attractiveness Analysis, by Product Type, 2015
Figure 31: North America Market Attractiveness Analysis, by Distribution Channel, 2015
Figure 32: Europe Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 33: Europe Market Attractiveness Analysis, by Country, 2015
Figure 34: Europe Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 35: Europe Market Value Share Analysis, by Distribution Channel, 2015 and 2024
Figure 36: Europe Market Value Share Analysis, by Country, 2015 and 2024
Figure 37: Europe Market Attractiveness Analysis, by Product Type, 2015
Figure 38: Europe Market Attractiveness Analysis, by Distribution Channel, 2015 
Figure 39: Asia Pacific Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 40: Asia Pacific Market Attractiveness Analysis, by Country, 2015
Figure 41: Asia Pacific Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 42: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2015 and 2024
Figure 43: Asia Pacific Market Value Share Analysis, by Country, 2015 and 2024
Figure 44: Asia Pacific Market Attractiveness Analysis, by Product Type, 2015
Figure 45: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2015
Figure 46: Latin America Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 47: Latin America Market Attractiveness Analysis, by Country, 2015
Figure 48: Latin America Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 49: Latin America Market Value Share Analysis, by Distribution Channel, 2015 and 2024
Figure 50: Latin America Market Value Share Analysis, by Country, 2015 and 2024
Figure 51: Latin America Market Attractiveness Analysis, by Product Type, 2015
Figure 52: Latin America Market Attractiveness Analysis, by Distribution Channel, 2015
Figure 53: Middle East & Africa Radiodermatitis Market Size (US$ Mn) Forecast, 2016–2024
Figure 54: Middle East & Africa Market Attractiveness Analysis, by Country, 2015
Figure 55: Middle East & Africa Market Value Share Analysis, by Product Type, 2015 and 2024
Figure 56: Middle East & Africa Market Value Share Analysis by Distribution Channel, 2015 and 2024
Figure 57: Middle East & Africa Market Value Share Analysis, by Country, 2015 and 2024
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Product Type, 2015
Figure 59: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2015
Figure 60: Global Radiodermatitis Market Share Analysis by Company (2015)

List of Tables

Table 1: Global Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 2: Global Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 3: List of Discontinued Clinical Trials
Table 4: List of Open Clinical Trials
Table 5: Global Radiodermatitis Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 6: North America Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 7: North America Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 8: North America Radiodermatitis Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 9: Europe Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 10: Europe Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 11: Europe Radiodermatitis Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 12: Asia Pacific Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 13: Asia Pacific Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 14: Asia Pacific Radiodermatitis Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 15: Latin America Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 16: Latin America Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 17: Latin America Radiodermatitis Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 18: Middle East & Africa Radiodermatitis Market Size (US$ Mn) Forecast, by Product Type, 2014–2024
Table 19: Middle East & Africa Radiodermatitis Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 20: Middle East & Africa Radiodermatitis Market Size (US$ Mn) Forecast, by Country, 2016–2024

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cancer radiotherapy, cumulative daily doses of radiation to the treatment field or target site on the body prevents normal skin to repopulate and weakens the skin integrity at and around the radiation field. Radiodermatitis may be acute or chronic and encompasses localized erythema, skin shedding (desquamation), hair loss (epilation), fibrosis, necrosis, and other similar conditions. Radiodermatitis affects a patient’s quality of life, causes pain and discomfort, and hinders in the continuous treatment regimes. Radiodermatitis can also cause interruption in or cessation of treatment, depending on the severity of reaction.

This report on the global radiodermatitis market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as increasing preference for efficacious products, product innovation, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global radiodermatitis market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Based on product type, the global radiodermatitis market has been segmented into topical, oral medication and dressings. The market has been further studied from the point of view of major type of topical applicants, oral medication, and dressings used for radiation dermatitis treatment. The topical segment is sub-segmented into topical corticosteroids, hydrophilic creams, and others (topical antibiotics). The oral medication segment comprises oral corticosteroids and others (oral analgesic and antibiotics). Hydrogel, hydrocolloid, no sting barrier film, honey impregnated gauze, silicone coated dressing, and others (silver leaf dressings, GM-CSF gauze, etc.) form the major sub-segments of the dressings segment. Consumer buying behavior is inclined toward dressings and topical products due to ease of use and suitability in the treatment of radiodermatitis symptoms.

The major distribution channels for sale of radiation dermatitis products include hospital pharmacy, retail pharmacy store, and online store. Online store is set to witness rapid growth due to the various benefits rendered to a radiodermatitis affected patient unwilling to visit outdoor medical stores. These benefits include easy shipping, huge discounts, and convenience of purchasing from any location.

Geographically, the global radiodermatitis market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market. The report also profiles major players in the radiodermatitis market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include 3M Health Care, BMG Pharma, Molnlycke Health Care, Smith & Nephew plc., Derma Sciences, Inc., Alliqua Biomedical, Acelity LP, Intermed Pharmaceuticals, and Stratpharma AG.

The global radiodermatitis market has been segmented as follows:

Global Radiodermatitis Market, by Product

  • Topical
    • Corticosteroids
    • Hydrophilic Creams
    • Others (topical antibiotics)
  • Oral Medication
    • Corticosteroids
    • Other (oral analgesics, antibiotics, etc.)
  • Dressings
    • Hydrogel
    • Hydrocolloid
    • No Sting Barrier Film
    • Honey Impregnated Gauze
    • Silicone Coated Dressing
    • Others (GM-CSF gauze, silver leaf dressing, etc.)

Global Radiodermatitis Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy Store
  • Online Store

Global Radiodermatitis Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top